Adzenys Er, Adzenys Xr-odt, Dyanavel (amphetamine) is a small molecule pharmaceutical. Amphetamine was first approved as Adzenys Er on 2015-10-19. It is used to treat attention deficit disorder with hyperactivity and narcolepsy in the USA. The pharmaceutical is active against sodium-dependent dopamine transporter and sodium-dependent noradrenaline transporter. In addition, it is known to target carbonic anhydrase 5A, mitochondrial, trace amine-associated receptor 1, and carbonic anhydrase 7. Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate's patents are valid until 2032-06-28 (FDA).
|Trade Name||Adzenys Er, Adzenys Xr-odt, Dyanavel|
|Indication||attention deficit disorder with hyperactivity, narcolepsy|
|Drug Class||Cns stimulant, anorectic|